Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2005-01-19
2010-11-02
Helms, Larry R. (Department: 1642)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C514S002600, C530S350000
Reexamination Certificate
active
07824685
ABSTRACT:
This invention relates to a gene encoding RTVP that has been shown to be up-regulated by p53 using differential display-PCR and subsequently by co-transfection studies. RTVP-1 mRNA is abundant in normal mouse and human prostatic epithelial cells and primary tumors, but is significantly down regulated in metastatic mouse and human prostate cancer. In prostate cancer cells overexpression of the mouse RTVP-1 gene (mRTVP-1) induced apoptosis that was accompanied by increased caspase 8, 9 and 3 activities. mRTVP-1-stimulated apoptosis was also associated with increased levels of bax, bad and activated BID; reduced levels of bcl-2 and bcl-XL; and cytosolic cytochrome c accumulation. Adenoviral-vector-mediated mRTVP-1 expression lead to potent growth suppression and antimetastatic activities in an orthotopic mouse model of prostate cancer in vivo. These therapeutic activities were associated with anti-angiogenic effects and importantly a local and systemic immune response. Accordingly, p53 was linked with suppression of metastasis through its induction of mRTVP-1, which can concurrently induce apoptosis, suppress angiogenesis and stimulate an antitumor immune response. Thus, the invention includes compositions and methods, based on RTVP nucleic acid, polypeptides, and antibodies, for use in the treatment, prevention and detection of neoplastic disease and, specifically, metastatic prostatic neoplasia.
REFERENCES:
patent: 6071874 (2000-06-01), Bandman et al.
patent: 6335170 (2002-01-01), Orntoft et al.
patent: 6783969 (2004-08-01), Tang et al.
patent: 2002/0052025 (2002-05-01), Thompson et al.
patent: 2002/0052308 (2002-05-01), Rosen et al.
patent: 2003/0119009 (2003-06-01), Stuart et al.
patent: 2003/0144494 (2003-07-01), Algate et al.
patent: 2003/0219743 (2003-11-01), Tang et al.
patent: 2003/0236392 (2003-12-01), Isogai et al.
patent: 2004/0009508 (2004-01-01), Thompson et al.
patent: 2004/0029151 (2004-02-01), Mahadevappa et al.
patent: 2005/0112129 (2005-05-01), Phillips
patent: 2007/0049743 (2007-03-01), Tang et al.
patent: WO 98/29448 (1998-07-01), None
patent: WO 2004/111200 (2004-12-01), None
patent: WO 2005/002413 (2005-01-01), None
Drexler et al, 1993 (Leukemia and Lymphoma, 9:1-25).
Embleton et al, 1984 (Immunol Ser, 23:181-207).
Hsu, 1973 (in Tissue Culture Methods and Applications, Kruse and Patterson, Eds, Academic Press, NY, see abstract, p. 764).
Tian, J et al, 2004 (Physiol Genomics, 17: 170-182).
Bowie (Science, 1990, 257:1306-1310).
Burgess et al ( J of Cell Bio. 111:2129-2138, 1990).
Lazar et al (Molecular and Cellular Biology, 1988, 8:1247-1252).
Stedman's medical dictionary, 25th ed, 1990, p. 1029-1030.
MPSRCH search report, 2007, us-11.038.285a-5-copy-22-232.rpr, result 1, pp. 1-2.
MPSRCH search result, 2009, us-11-038-285.9.rapbm, result 5, p. 1.
Santourlidis et al, 2001, Mol carcinogenesis, 32: 36-43.
Gazin et al, 2007, Nature, 449 (7165): 1073-1077.
El-Deiry “Regulation of p53 downstream genes”, Semin.Cancer Biol., vol. 8, No. 5, pp. 345-357. 1998.
Giaccia et al. “The complexity of p53 modulation: emerging patterns from divergent signals”, Genes Dev., vol. 12, No. 19, pp. 2973-2983. Oct. 1, 1998.
Burns et al. “The p53 pathway and apoptosis”, J.Cell Physiol, vol. 181, No. 2, pp. 231-239. Nov. 1999.
Vogelstein et al. “p53 function and dysfunction”, Cell, vol. 70, No. 4, pp. 523-526. Aug. 21, 1992.
Thompson et al. “Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer”, Oncogene, vol. 10, No. 5, pp. 869-879. Mar. 2, 1995.
Thompson et al. “Oncogenes, growth factors, and hormones in prostate cancer”, in Hormones and growth factors in development and neoplasia. Wiley-Liss, Inc., New York, 1998, pp. 327-359.
Navone et al. “p53 protein accumulation and gene mutation in the progression of human prostate carcinoma”, J.Natl.Cancer Inst., vol. 85, No. 20, pp. 1657-1669. Oct. 20, 1993.
Eastham et al. “Association of p53 mutations with metastatic prostate cancer”, Clin.Cancer Res, vol. 1, No. 10, pp. 1111-1118. Oct. 1995.
Yang et al. “Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression”, Clin.Cancer Res, vol. 2, No. 2, pp. 399-401. Feb. 1996.
Mirchandani et al. “Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer”, Am.J.Pathol., vol. 147, No. 1, pp. 92-101. Jul. 1995.
Stapleton et al. “Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases”, Clin.Cancer Res, vol. 3, No. 8, pp. 1389-1397. Aug. 1997.
Quinn et al. “Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy”, Cancer Res, vol. 60, No. 6, pp. 1585-1594. Mar. 15, 2000.
Stapleton et al. “Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery”, Cancer, vol. 82, No. 1, pp. 168-175. Jan. 1, 1998.
Miyashita et al. “Tumor suppressor p53 is a direct transcriptional activator of the human bax gene”, Cell, vol. 80, No. 2, pp. 293-299. Jan. 27, 1995.
Sheikh et al. “p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha”, Cancer Res, vol. 58, No. 8, pp. 1593-1598. Apr. 15, 1998.
Oda et al. “p53AlP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53”, Cell, vol. 102, No. 6, pp. 849-862. Sep. 15, 2000.
Zhu et al. “MCG10, a novel p53 target gene that encodes a KH domain RNA-binding protein, is capable of inducing apoptosis and cell cycle arrest in G(2)-M”, Mol.Cell Biol., vol. 20, No. 15, pp. 5602-5618. Aug. 2000.
Dameron et al. “Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1”, Science, vol. 265, No. 5178, pp. 1582-1584. Sep. 9, 1994.
Lopez-Ocejo et al. “Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner”, Oncogene, vol. 19, No. 40, pp. 4611-4620. Sep. 21, 2000.
Zou et al. “p53 regulates the expression of the tumor suppressor gene maspin”, J.Biol.Chem., vol. 275, No. 9, pp. 6051-6054. Mar. 3, 2000.
Zhang et al. “Maspin is an angiogenesis inhibitor”, Nat.Med., vol. 6, No. 2, pp. 196-199. Feb. 2000.
Murphy et al. “The human glioma pathogenesis-related protein is structurally related to plant pathogenesis-related proteins and its gene is expressed specifically in brain tumors”, Gene, vol. 159, No. 1, pp. 131-135. Jun. 14, 1995.
Zhang et al. “Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1”, Proc.Natl.Acad.Sci.U.S.A, vol. 97, No. 12, pp. 6427-6432. Jun. 6.
Rich et al. “RTVP-1, a novel human gene with sequence similarity to genes of diverse species, is expressed in tumor cell lines of glial but not neuronal origin”, Gene, vol. 180, No. 1-2, pp. 125-130. Nov. 21, 1996.
Gingras et al. “Differential expression of multiple unexpected genes during U937 cell and macrophage differentiation detected by suppressive subtractive hybridization”, Exp.Hematol., vol. 28, No. 1, pp. 65-76. Jan. 2000.
Cho et al. “Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations”, Science, vol. 265, No. 5170, pp. 346-355. Jul. 15, 1994.
Tokino et al. “p53 tagged sites from human genomic DNA”, Hum.Mol.Genet., vol. 3, No. 9, pp. 1537-1542. Sep. 1994.
Yu et al. “Identification and classification of p53-regulated genes”, Proc.Natl.Acad.Sci.U.S.A, vol. 96, No. 25, pp. 14517-14522. Dec. 7, 1999.
Shiraishi et al. “Identification of fractalkine, a CX3C-type chemokine, as a direct target of p53”, Cancer Res, vol. 60, No. 14, pp. 3
Ren Chengzhen
Thompson Timothy C.
Baylor College of Medicine
Davis Minh-Tam
Helms Larry R.
Vinson & Elkins L.L.P.
LandOfFree
RTVP based compositions and methods for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with RTVP based compositions and methods for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and RTVP based compositions and methods for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4226942